Bellinda King-Kallimanis, PhD of U.S. Food and Drug Administration, Maryland (FDA ) discusses Incorporating Relevant and Meaningful ?Patient-Reported Outcomes in ?RCC Clinical Trials? at the Seventeenth International Kidney Cancer International Symposium 2018 in Miami FL.
Incorporating Relevant and Meaningful ?Patient-Reported Outcomes in ?RCC Clinical Trials?
